| Treatment success, n (%) |
|||||
|---|---|---|---|---|---|
| Two-arm trial (PPS) |
Three-arm trial (FAS) |
||||
| MICA100 | L-AmB | MICA100 | MICA150 | CAS | |
| C. albicans | 76/86 (88.4) | 75/84 (89.3) | 71/93 (76.3) | 71/102 (69.6) | 62/84 (73.8) |
| Non-albicans Candida species | 113/126 (89.7) | 100/112 (89.3) | 84/111 (75.7) | 74/107 (69.2) | 85/122 (69.7) |
| C. glabrata | 19/23 (82.6) | 12/15 (80.0) | 24/28 (85.6) | 30/34 (88.2) | 22/33 (66.7) |
| C. tropicalis | 48/52 (92.3) | 41/43 (95.3) | 21/31 (67.7) | 20/33 (60.6) | 24/32 (75.0) |
| C. parapsilosis | 33/37 (89.2) | 26/30 (86.7) | 23/30 (76.7) | 15/21 (71.4) | 27/42 (64.3) |
| C. krusei | 5/6 (83.3) | 6/7 (85.7) | 6/8 (75.0) | 5/8 (62.5) | 3/4 (75.0) |
| C. guilliermondii | 4/4 (100) | 4/4 (100) | 3/3 (100) | 2/2 (100) | 1/1 (100) |
| C. lusitaniae | 1/1 (100) | 2/2 (100) | 3/3 (100) | 0/1 | 3/3 (100) |
| C. famata | 3/3 (100) | 1/1 (100) | − | − | − |
Only Candida species observed in ≥3 patients in either study are included in the table. Patients could be diagnosed with more than one organism at baseline.